BYND Cannasoft Enterprises, Inc. develops, markets and sells a proprietary client relationship management software known as Benefit CRM and Cannabis CRM platform. It also develops the EZ-G device, a patent-pending device that, combined with proprietary software. The company was founded on March 29, 2021 and is headquartered in Kiryat Motzkin, Israel.

Foresight Autonomous Holdings Ltd. is engaged in the research and development of vehicular accident prevention products. Its product is QuadSight, a multi-spectral vision solution for detection of obstacles in harsh lightining and weather conditions. The company was founded by Haim Siboni on September 19, 1977 and is headquartered in Ness Ziona, Israel.

SilverSun Technologies, Inc. is a business application, technology and consulting company. It is engaged in providing transformative business management solutions, technologies and professional consulting services to small and medium-sized businesses in the manufacturing, distribution and service industries. The firm offers solutions for accounting and business management, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, and business intelligence. The company was founded on October 3, 2002 and is headquartered in East Hanover, NJ.

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Sezzle, Inc. engages in the operation of a payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie Youakim, Killian Brackey and Paul Paradis in 2016 and is headquartered in Minneapolis, MN.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.